Forsta AP Fonden Has $35.24 Million Stake in Danaher Co. (NYSE:DHR)

Forsta AP Fonden lessened its position in shares of Danaher Co. (NYSE:DHR) by 5.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 153,522 shares of the conglomerate’s stock after selling 8,700 shares during the period. Forsta AP Fonden’s holdings in Danaher were worth $35,241,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Wedge Capital Management L L P NC grew its position in shares of Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 38 shares during the last quarter. Meridian Financial Partners LLC increased its holdings in shares of Danaher by 4.4% during the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after buying an additional 40 shares in the last quarter. Kovack Advisors Inc. boosted its stake in shares of Danaher by 3.4% during the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after purchasing an additional 41 shares in the last quarter. Well Done LLC raised its stake in shares of Danaher by 1.2% during the third quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock valued at $987,000 after acquiring an additional 42 shares during the last quarter. Finally, Waypoint Capital Advisors LLC lifted its holdings in Danaher by 0.9% during the 3rd quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock worth $1,257,000 after buying an additional 42 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 1.1 %

Danaher stock opened at $247.77 on Wednesday. The stock has a market cap of $178.96 billion, a PE ratio of 47.29, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. Danaher Co. has a one year low of $225.42 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock has a 50-day moving average of $236.09 and a two-hundred day moving average of $253.66.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. During the same period last year, the company earned $2.09 EPS. On average, research analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio is currently 20.61%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Evercore ISI increased their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Stephens reissued an “overweight” rating and set a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. Robert W. Baird decreased their price objective on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a report on Tuesday. Citigroup dropped their price target on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Finally, Scotiabank started coverage on shares of Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price objective for the company. Six research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $285.81.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.